Stoke Therapeutics (STOK) Net Cash Flow (2018 - 2026)

Stoke Therapeutics' Net Cash Flow history runs 9 years deep, the most recent figure standing at $74.4 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 49.3% year-over-year to $74.4 million; the TTM figure through Mar 2026 stood at -$116.2 million (down 220.5% YoY), while the FY2025 annual figure was -$43.8 million, up 30.67% from the prior year.
• Net Cash Flow was $74.4 million for Q1 2026 at Stoke Therapeutics, up from $826000.0 in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $146.8 million in Q1 2025 to a low of -$173.3 million in Q2 2025.
• Historically, Net Cash Flow has averaged $818588.2 across 5 years, with a median of $160000.0 in 2022.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow plunged 1986.41% in 2024, then surged 1241.69% in 2025.
• A 5-year view of Net Cash Flow shows it stood at $160000.0 in 2022, then soared by 815.62% to $1.5 million in 2023, then sank by 1588.46% to -$21.8 million in 2024, then surged by 103.79% to $826000.0 in 2025, then jumped by 8911.99% to $74.4 million in 2026.
• The last three Net Cash Flow figures came in at $74.4 million (Q1 2026), $826000.0 (Q4 2025), and -$18.2 million (Q3 2025), per Business Quant data.